



## Communication

# *N*-(2-Phenoxy)ethyl imidazo[1,2-*a*]pyridine-3-carboxamides containing various amine moieties: Design, synthesis and antitubercular activity

Linhu Li<sup>a,b,1</sup>, Apeng Wang<sup>a,1</sup>, Bin Wang<sup>c</sup>, Mingliang Liu<sup>a,\*</sup>, Kai Lv<sup>a</sup>, Zeyu Tao<sup>a</sup>, Chao Ma<sup>a</sup>, Xican Ma<sup>a</sup>, Bing Han<sup>a</sup>, Aoyu Wang<sup>a</sup>, Yu Lu<sup>c,\*</sup>

<sup>a</sup> Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

<sup>b</sup> Limin Chemical Co., Ltd., Xinyi 221422, China

<sup>c</sup> Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 100149, China



## ARTICLE INFO

## Article history:

Received 22 June 2019

Received in revised form 12 July 2019

Accepted 16 July 2019

Available online 17 July 2019

## Keywords:

*N*-(2-Phenoxy)ethyl imidazo[1,2-*a*]pyridine

Design

Synthesis

Antimycobacterial activity

## ABSTRACT

Seven 2,6-disubstituted *N*-(2-phenoxy)ethyl imidazo[1,2-*a*]pyridine-3-carboxamide series containing various amine moieties were designed and synthesized as new anti-TB agents. Many of them show excellent *in vitro* activity against both drug-sensitive MTB strain H37Rv and two MDR-MTB clinical isolates (MIC: < 0.002–0.030 μg/mL). Compounds **2f**, **5e** and **5g** display acceptable safety and pharmacokinetic profiles, opening a new direction for further development.

© 2019 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Published by Elsevier B.V. All rights reserved.

Tuberculosis (TB), which is mainly caused by *Mycobacterium tuberculosis* (MTB), remains one of the world's deadliest pandemic diseases with approximately 10.0 million new TB cases and 1.6 million TB-related deaths estimated by the WHO in 2017 [1]. The sprawl of multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR) TB have created an urgent demand for the discovery and development of novel TB drugs to improve the treatment outcomes [2–4]. Encouragingly, bedaquiline and delamanid have been approved for the treatment of MDR-TB, although some adverse events have been noted [5]. Considering the high attrition rate in new drug development, there is still a great need for safer and more effective candidates with novel mechanisms of action [6].

Imidazo[1,2-*a*]pyridine-3-carboxamides (IPAs) as new anti-TB agents targeting QcrB [7] have garnered great interest recently. The candidate Q203 (Fig. 1) is in phase II clinical trials at present [1], and many series of new IPAs were reported to have potent antimycobacterial activity [8–19]. Structure-activity relationship (SAR) studies of IPAs demonstrate that the carboxamide linker with the

*N*-benzyl group is critical for anti-MTB activity [16]. In our previous studies [17–19], however, some *N*-(2-phenoxy)ethyl IPAs exemplified by WZY02 (Fig. 1), have been identified as new anti-TB agents with strong *in vitro* anti-MTB activity. Herein we report on the additional SAR studies of 2,6-disubstituted *N*-(2-phenoxy)ethyl IPAs containing various amine moieties. Our primary objective was to find new IPA derivatives with potent anti-MTB activity and facilitate the further development of these compounds.

The synthesis of target compounds **1–7** are shown in Scheme 1. As our previous procedures [20], IPA core acids **16–22** were easily obtained *via* microwave assistant cyclization of pyridine-amines **8–14** and esters **15**, and then hydrolysis. Buchwald-Hartwig amination of THP (tetrahydro-2*H*-pyran)-protected bromophenol **23** with amines gave condensates **24b–j**, and removal of the THP group of **24b–j** yielded *para*-aminophenols **25b–j**. Nucleophilic substitution of **25b–j** and commercially available **25a** with bromoacetonitrile, and then reduction gave 4-(2-aminoethoxy)-anilines **26a–j**. Coupling of acids **16–22** with side-chain compounds **26a–j** achieved IPA derivatives **1–7**.

The target compounds **1–7** were initially screened for *in vitro* activity against MTB H37Rv ATCC 27294 strain using the Microplate Alamar Blue Assay (MABA) [21,22]. The minimum inhibitory concentration (MIC) is defined as the lowest concentration effecting a reduction in fluorescence of >90% relative to the mean

\* Corresponding authors.

E-mail addresses: [lmlyx@126.com](mailto:lmlyx@126.com) (M. Liu), [luyu4876@hotmail.com](mailto:luyu4876@hotmail.com) (Y. Lu).

<sup>1</sup> These authors contributed equally to this work.






Fig. 1. Structures of Q203 and WZY02.



**Scheme 1.** Synthesis of 1–7. Reagents and conditions: (a) MW, EtOH, 120 °C; (b) LiOH, THF, H<sub>2</sub>O, 0–5 °C; (c) (±)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene, Cs<sub>2</sub>CO<sub>3</sub>, palladium(II) acetate, amines, toluene, reflux; (d) EtOH, 4-methylbenzenesulfonate, pyridin-1-ium; reflux; (e) K<sub>2</sub>CO<sub>3</sub>, bromoacetonitrile, DMSO, r.t.; (f) LiAlH<sub>4</sub>, THF, r.t.; (g) BOP-Cl, Et<sub>3</sub>N, DCM, r.t.

Table 1

Structures and activity of compounds 1–7 against MTB H37Rv.



Compd.	R <sub>1</sub>	R <sub>2</sub>	W	MIC (μg/mL)	Compd.	R <sub>1</sub>	R <sub>2</sub>	W	MIC (μg/mL)	Compd.	R <sub>1</sub>	R <sub>2</sub>	W	MIC (μg/mL)
WZY02	Me	Me	-Br	0.031	3c	Me	c-Pr	c	0.201	6a	Br	Et	a	0.031
1a	Me	Me	a	0.118	3d	Me	c-Pr	d	<0.016	6c	Br	Et	c	<0.016
1b	Me	Me	b	0.021	3e	Me	c-Pr	e	<0.016	6d	Br	Et	d	<0.016
1c	Me	Me	c	0.043	3f	Me	c-Pr	f	0.071	6f	Br	Et	f	0.030
1d	Me	Me	d	<0.016	3g	Me	c-Pr	g	0.030	6g	Br	Et	g	0.019
1e	Me	Me	e	<0.016	3h	Me	c-Pr	h	0.020	6h	Br	Et	h	0.020
1f	Me	Me	f	0.027	3i	Me	c-Pr	i	<0.016	7a	Cl	c-Pr	a	0.679
1g	Me	Me	g	0.024	4a	OMe	Me	a	0.028	7b	Cl	c-Pr	b	0.028
1h	Me	Me	h	0.018	4b	OMe	Me	b	0.024	7c	Cl	c-Pr	c	1.489
1i	Me	Me	i	<0.016	4c	OMe	Me	c	0.090	7d	Cl	c-Pr	d	0.056
1j	Me	Me	j	6.926	4d	OMe	Me	d	0.026	7e	Cl	c-Pr	e	<0.016
2a	Me	Et	a	0.021	4f	OMe	Me	f	0.024	7f	Cl	c-Pr	f	0.402
2b	Me	Et	b	0.020	4g	OMe	Me	g	0.019	7g	Cl	c-Pr	g	0.032
2c	Me	Et	c	<0.016	4h	OMe	Me	h	<0.016	7h	Cl	c-Pr	h	0.062
2d	Me	Et	d	<0.016	5b	Cl	Et	b	0.020	7i	Cl	c-Pr	i	0.105
2e	Me	Et	e	<0.016	5c	Cl	Et	c	0.045	Q203				<0.016
2f	Me	Et	f	<0.016	5d	Cl	Et	d	0.029	PBTZ169				<0.016
2g	Me	Et	g	<0.016	5e	Cl	Et	e	<0.016	RFP				0.050
2h	Me	Et	h	<0.016	5f	Cl	Et	f	0.052	INH				0.049
3a	Me	c-Pr	a	0.031	5g	Cl	Et	g	<0.016					
3b	Me	c-Pr	b	<0.016	5i	Cl	Et	i	<0.016					

**Table 2**  
Anti-MDR-MTB activity and cytotoxicity of selected compounds.

Compd.	MIC ( $\mu\text{g/mL}$ )		Vero cells $\text{CC}_{50}^a$ ( $\mu\text{g/mL}$ )	Compd.	MIC ( $\mu\text{g/mL}$ )		Vero cells $\text{CC}_{50}^a$ ( $\mu\text{g/mL}$ )
	MDR-1	MDR-2			MDR-1	MDR-2	
<b>1d</b>	<0.002	0.003	19.65	<b>3i</b>	<0.002	<0.002	>64
<b>1e</b>	<0.002	0.003	>64	<b>4h</b>	<0.002	<0.002	36.57
<b>1i</b>	<0.002	<0.002	>64	<b>5e</b>	<0.002	<0.002	>64
<b>2c</b>	0.004	0.007	>64	<b>5g</b>	<0.002	<0.002	>64
<b>2d</b>	<0.002	<0.002	>64	<b>5i</b>	<0.002	<0.002	>64
<b>2e</b>	<0.002	<0.002	58.80	<b>6c</b>	0.028	0.030	>64
<b>2f</b>	<0.002	<0.002	>64	<b>6d</b>	0.003	0.003	>64
<b>2g</b>	<0.002	<0.002	61.44	<b>7e</b>	<0.002	0.003	58.16
<b>2h</b>	<0.002	<0.002	62.22	Q203	<0.002	<0.002	>64
<b>3b</b>	<0.002	<0.002	>64	PBTZ169	<0.002	<0.002	>64
<b>3d</b>	0.003	0.005	>64	RFP	>40	>40	NT
<b>3e</b>	<0.002	<0.002	>64	INH	>40	>40	NT

MDR-1 is MDR-MTB 16995 and MDR-2 is MDR-MTB 16833, which were isolated from patients in Beijing Chest Hospital; NT: not tested.

<sup>a</sup> The 50% cytotoxic concentration.

**Table 3**  
*In vivo* PK profiles of selected compounds dosed orally in ICR female mice at 25 mg/kg ( $n = 3$ ).

Compd.	$t_{1/2}$ (h)	$t_{\text{max}}$ (h)	$C_{\text{max}}$ (ng/mL)	$\text{AUC}_{0-\infty}$ (h ng/mL)	MRT (h)
<b>2d</b>	0.736 $\pm$ 0.15	0.25 $\pm$ 0	218 $\pm$ 71	120 $\pm$ 39	0.736 $\pm$ 0.17
<b>2f</b>	1.24 $\pm$ 0.14	0.25 $\pm$ 0	3198 $\pm$ 764	2234 $\pm$ 759	0.769 $\pm$ 0.08
<b>5e</b>	1.04 $\pm$ 0.08	0.42 $\pm$ 0.14	1555 $\pm$ 299	2466 $\pm$ 1218	1.37 $\pm$ 0.20
<b>5g</b>	4.74 $\pm$ 0.55	0.667 $\pm$ 0.29	763 $\pm$ 267	2835 $\pm$ 671	4.27 $\pm$ 0.12

of replicate bacterium-only controls. The MIC values of the compounds along with isoniazid (INH), rifampicin (RFP), Q203, PBTZ169 and the lead compound WZY02 for comparison are presented in Table 1. Detailed procedures are shown in Supporting information. The data reveal that most of them have good potency against this strain (MIC: < 0.05  $\mu\text{g/mL}$ ). Twenty compounds were found to show the same excellent activity (MIC: < 0.016  $\mu\text{g/mL}$ ) as Q203 and PBTZ169, while being more active than INH, RFP and WZY02 (MIC: 0.031–0.059  $\mu\text{g/mL}$ ).

We first investigated the potential impact of various amines on the anti-MTB activity of the 2,6-dimethyl IPA series. Replacement of the bromine atom on the *para*-position of the benzene ring of the lead WZY02 (MIC: 0.031  $\mu\text{g/mL}$ ) with dimethylamine group in compound **1a** leads to decreased activity (MIC: 0.118  $\mu\text{g/mL}$ ), but the presence of piperidine in compound **1b** demonstrates better potent MIC value of 0.021  $\mu\text{g/mL}$ , suggesting that cyclic amine is preferred over non-cyclic one. And this phenomenon is also observed in compounds **1c** and **1d** containing morpholine and thiomorpholine rings, the isostere of the piperidine (**1b**), respectively.

Further investigation reveals that introduction of an electron-withdrawing group, a methyloxime (a known functional moiety of the third and fourth generational cephalosporins) or an aromatic moiety on the *para*-position of the piperidine ring is acceptable, such as compounds **1e–g** with MIC of <0.016–0.027  $\mu\text{g/mL}$ . As expected, the piperidine ring of **1g** could be replaced by its isostere piperazine (**1h**, MIC: 0.018  $\mu\text{g/mL}$ ) without obviously affecting the anti-MTB potency. Interestingly, compound **1i** with a fused nitrogen heterocycle (octahydro-1*H*-isoindole) shows the best activity (MIC: < 0.016  $\mu\text{g/mL}$ ). However, introduction of an additional piperidyl group on the *para*-position of the piperidine ring of **1b** is detrimental, and the resulting compound **1j** shows poor activity (MIC: 6.926  $\mu\text{g/mL}$ ) probably due to the alkaline of the terminal piperidine ring, indicating that 1,4'-bipiperidine is unacceptable as the W group. The above results suggest that all the amines with an exception of 1,4'-bipiperidine (**j**), could be ideally suited as the W groups.

Subsequently, the effect of the  $R_1$  and  $R_2$  groups on the anti-MTB activity of other six 2,6-disubstituted IPA series with nine amine moieties (**a–i**) was further investigated. With a few exceptions, as shown in Table 1, replacement of the methyl group ( $R_2$ ) on the core of 2,6-dimethyl IPA series **1a–i** with ethyl (**2a–i**) results to slightly increased potency, but cyclopropyl (c-Pr) as  $R_2$  (**3a–i**) has not obvious influence on the activity, indicating that ethyl group as  $R_2$  is preferred over methyl and cyclopropyl. Moreover, the C-6 position of the IPA core is also well tolerated by another electron-donating OMe group (**1a–i** vs. **4a–i**).

In further modifications, the methyl group of series **2** or **3** was replaced by a halogen atom as the  $R_1$  group. 6-Chloro-2-ethyl IPA derivatives **5** with the same core of Q203, As shown in Table 1, display roughly the same activity (MIC: < 0.016–0.052  $\mu\text{g/mL}$ ) as the corresponding analogues **2**. Replacement of the chlorine atom of series **5** with bromine does not affect significantly the activity (**5** vs. **6**). But the presence of cyclopropyl group instead of the ethyl as the  $R_2$  group (**5** vs. **7**), or chlorine instead of the methyl as the  $R_1$  group (**3** vs. **7**) seems to be unfavorable. Overall, the above results indicate that anti-MTB activity of the *N*-(2-phenoxy)ethyl IPA derivatives is related to  $R_1$  and  $R_2$  groups of the IPA core as well as W on the *para*-position of the benzene ring.

Encouraged by their potent activity (MIC: <0.016  $\mu\text{g/mL}$ ) against drug sensitive MTB H37Rv strain, 20 compounds were evaluated against two clinical isolated MTB-MDR (16995 and 16833) strains resistant to both INH and RFP. As shown in Table 2, all of them exhibit strong potency (MIC: <0.002–0.030  $\mu\text{g/mL}$ ), especially 13 compounds have the same best MIC values of < 0.002  $\mu\text{g/mL}$  as Q203 and PBTZ169, suggesting their promising potential for both drug-sensitive and resistant MTB strains (Tables 1 and 2).

The above 20 compounds were also tested for mammalian cell cytotoxicity using Vero cells measured as a concentration inhibiting 50% growth ( $\text{CC}_{50}$ ) as compared to a no-treatment control [22]. As shown in Table 2, 14 compounds show low cytotoxicity ( $\text{CC}_{50}$ : > 64  $\mu\text{g/mL}$ ) comparable to Q203 and PBTZ169. Detailed procedures are shown in Supporting information.

Based on the measured activity against all the tested strains and cell cytotoxicity, 4 compounds **2d**, **2f**, **5e** and **5h** were further evaluated for their *in vivo* pharmacokinetic (PK) profiles in ICR female mice after a single oral administration of 25 mg/kg. Compared with **2d**, as shown in Table 3, methyloxime-containing compound **2f** with the same 2-ethyl-6-methyl IPA core, displays significantly higher  $C_{max}$  (3198 ng/mL),  $AUC_{0-\infty}$  (2234 h ng/mL) and longer  $t_{1/2}$  (1.24 h). Although compound **5e** shows acceptable PK profiles, its analogue **5g** with 4-fluorophenyl instead of trifluoromethyl group on the *para*-position of the piperidine ring demonstrates higher  $AUC_{0-\infty}$  (2835 h ng/mL) and longer  $t_{1/2}$  (4.74 h). Detailed procedures are shown in Supporting information.

In conclusion, seven 2,6-disubstituted *N*-(2-phenoxy)ethyl IPA series containing various amine moieties were designed and synthesized as new anti-TB agents. Many of them exhibit excellent *in vitro* inhibitory activity with low nanomolar MIC values against both drug-sensitive MTB strain H37Rv and two drug-resistant clinical isolates (MIC: < 0.002–0.030  $\mu$ g/mL), and low cytotoxicity ( $CC_{50}$ : > 64  $\mu$ g/mL). Particularly, compounds **2f**, **5e** and **5g** show acceptable PK profiles, suggesting they may serve as new and promising candidates for further study.

### Acknowledgments

This work is supported by the CAMS Innovation Fund for Medical Science (No. CAMS-2017-I2M-1-011), National Mega-project for Innovative Drugs (Nos. 2015ZX09102007-008, 2018ZX09721001-004-007, 2018ZX09711001-007-002), the National Natural Science Foundation of China (No. 81872753).

### Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.ccllet.2019.07.038>.

### References

- [1] World Health Organization, Global Tuberculosis Report, 2018. <http://www.who.int/tb/>.
- [2] Z. Xu, S. Zhang, C. Gao, et al., *Chin. Chem. Lett.* 28 (2017) 159–167.
- [3] Y. Zhang, R. Wang, T. Zhang, et al., *Chin. Chem. Lett.* 30 (2019) 653–655.
- [4] A. Wang, Y. Yang, Y. Jun, et al., *Bioorg. Med. Chem.* 26 (2018) 2073–2084.
- [5] Wang H, K. Lv, X. Li, et al., *Chin. Chem. Lett.* 30 (2019) 413–416.
- [6] S. Tiberi, R. Buchanan, J.A. Caminero, et al., *Presse Med.* 46 (2017) e41–e51.
- [7] K.A. Abrahams, J.A. Cox, V.L. Spivey, et al., *PloS One* 7 (2012) e52951.
- [8] G.C. Moraski, L.D. Markley, J. Cramer, et al., *ACS Med. Chem. Lett.* 4 (2013) 675–679.
- [9] G.C. Moraski, L.D. Markley, P.A. Hipskind, et al., *ACS Med. Chem. Lett.* 2 (2011) 466–470.
- [10] G.C. Moraski, L.D. Markley, M. Chang, et al., *Bioorg. Med. Chem.* 7 (2012) 2214–2220.
- [11] H. Wang, A. Wang, J. Gu, et al., *Eur. J. Med. Chem.* 165 (2019) 11–17.
- [12] A. Wang, H. Wang, Y. Geng, et al., *Bioorg. Med. Chem.* 27 (2019) 813–821.
- [13] S. Kang, Y.M. Kim, R.Y. Kim, et al., *Eur. J. Med. Chem.* 125 (2017) 807–815.
- [14] S. Kang, Y.M. Kim, H. Jeon, et al., *Eur. J. Med. Chem.* 136 (2017) 420–427.
- [15] G.C. Moraski, L.D. Markley, P.A. Hipskind, et al., *ACS Med. Chem. Lett.* 2 (2011) 466–470.
- [16] S. Kang, R.Y. Kim, M.J. Seo, et al., *J. Med. Chem.* 57 (2014) 5293–5305.
- [17] K. Lv, L. Li, B. Wang, et al., *Eur. J. Med. Chem.* 137 (2017) 117–125.
- [18] Z. Wu, Y. Lu, L. Li, et al., *ACS Med. Chem. Lett.* 7 (2016) 1130–1133.
- [19] A. Wang, K. Lv, L. Li, et al., *Eur. J. Med. Chem.* 175 (2019) 715–725.
- [20] L. Li, Z. Wu, M. Liu, et al., *Heterocycles* 91 (2015) 2087–2095.
- [21] L.A. Collins, S.G. Franzblau, *Antimicrob. Agents Chemother.* 41 (1997) 1004–1009.
- [22] Y. Lu, M. Zheng, B. Wang, et al., *Antimicrob. Agents Chemother.* 55 (2011) 5185–5193.